Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

• Judith Trotman,
• Peter Presgrave,
• Duncan P. Carradice,
• Douglas Stuart Lenton,
• Maher K. Gandhi,
• Tara Cochrane,
• Xavier Badoux,
• Julia Carlson,
• Gloria Nkhoma,
• Belinda Butcher,
• Armin Nikpour,
• Michael Fulham,
• Anna M. Johnston

Affiliations

Judith Trotman

1 Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

Peter Presgrave

3 Department of Haematology, Wollongong Hospital, NSW, Australia

Duncan P. Carradice

4 Department of Haematology and Medical Oncology, Western Health and University of Melbourne, St Albans, VIC, Australia

Douglas Stuart Lenton

5 Orange Hospital, NSW, Australia

Maher K. Gandhi

7 Princess Alexandra Hospital, Brisbane, QLD, Australia

Tara Cochrane

9 Department of Haematology, Gold Coast University Hospital, Southport, Australia

Xavier Badoux

11 University of New South Wales, Sydney, NSW, Australia

Julia Carlson

12 Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia

Gloria Nkhoma

12 Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia

Belinda Butcher

11 University of New South Wales, Sydney, NSW, Australia

Armin Nikpour

2 University of Sydney, Camperdown, NSW, Australia

Michael Fulham

2 University of Sydney, Camperdown, NSW, Australia

Anna M. Johnston

15 Department of Hematology, Royal Hobart Hospital, Hobart, TAS, Australia